TRADES
Latest Trades
98
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 21 Jan 2022 Buy EXAS EXACT SCIENCES CORP 181,365 0.3493
ARKG 20 Jan 2022 Buy EXAS EXACT SCIENCES CORP 172,207 0.3432
ARKG 12 Jan 2022 Buy EXAS EXACT SCIENCES CORP 41,103 0.0724
ARKG 11 Jan 2022 Buy EXAS EXACT SCIENCES CORP 300 0.0005
ARKG 10 Jan 2022 Buy EXAS EXACT SCIENCES CORP 49,498 0.0785
ARKK 27 Dec 2021 Sell EXAS EXACT SCIENCES CORP 25,880 0.0116
ARKK 26 Nov 2021 Buy EXAS EXACT SCIENCES CORP 317,307 0.1500
ARKG 24 Nov 2021 Buy EXAS EXACT SCIENCES CORP 131,954 0.2011
ARKK 24 Nov 2021 Buy EXAS EXACT SCIENCES CORP 105,800 0.0506
ARKK 23 Nov 2021 Buy EXAS EXACT SCIENCES CORP 411,502 0.1825
ARKG 22 Nov 2021 Buy EXAS EXACT SCIENCES CORP 140,517 0.1912
ARKK 22 Nov 2021 Buy EXAS EXACT SCIENCES CORP 44,709 0.0192
ARKG 9 Nov 2021 Buy EXAS EXACT SCIENCES CORP 77,868 0.1010
ARKK 9 Nov 2021 Buy EXAS EXACT SCIENCES CORP 35,273 0.0163
ARKK 8 Nov 2021 Buy EXAS EXACT SCIENCES CORP 72,841 0.0337
ARKK 5 Nov 2021 Buy EXAS EXACT SCIENCES CORP 1,392 0.0006
ARKK 4 Nov 2021 Buy EXAS EXACT SCIENCES CORP 81,080 0.0350
ARKG 3 Nov 2021 Buy EXAS EXACT SCIENCES CORP 136,157 0.1677
ARKK 3 Nov 2021 Buy EXAS EXACT SCIENCES CORP 507,479 0.2103
ARKG 2 Nov 2021 Buy EXAS EXACT SCIENCES CORP 23,795 0.0307
ARKG 1 Nov 2021 Buy EXAS EXACT SCIENCES CORP 261,557 0.3530
ARKG 29 Oct 2021 Buy EXAS EXACT SCIENCES CORP 63,127 0.0824
ARKG 28 Oct 2021 Buy EXAS EXACT SCIENCES CORP 1,016 0.0013
ARKG 27 Oct 2021 Buy EXAS EXACT SCIENCES CORP 83,000 0.1077
ARKG 26 Oct 2021 Buy EXAS EXACT SCIENCES CORP 26,180 0.0339
ARKK 29 Sep 2021 Buy EXAS EXACT SCIENCES CORP 172,222 0.0798
ARKK 28 Sep 2021 Buy EXAS EXACT SCIENCES CORP 159,436 0.0708
ARKG 18 Aug 2021 Buy EXAS EXACT SCIENCES CORP 134,729 0.1538
ARKK 17 Aug 2021 Buy EXAS EXACT SCIENCES CORP 112,596 0.0476
ARKK 16 Aug 2021 Buy EXAS EXACT SCIENCES CORP 244,663 0.1013
ARKG 30 Jul 2021 Buy EXAS EXACT SCIENCES CORP 79,839 0.1003
ARKK 30 Jul 2021 Buy EXAS EXACT SCIENCES CORP 69,673 0.0342
ARKG 29 Jul 2021 Buy EXAS EXACT SCIENCES CORP 81,371 0.1036
ARKK 29 Jul 2021 Buy EXAS EXACT SCIENCES CORP 340,429 0.1676
ARKK 16 Jul 2021 Buy EXAS EXACT SCIENCES CORP 70,285 0.0365
ARKK 15 Jul 2021 Buy EXAS EXACT SCIENCES CORP 224,559 0.1116
ARKG 14 Jul 2021 Buy EXAS EXACT SCIENCES CORP 82,938 0.1044
ARKK 1 Jun 2021 Buy EXAS EXACT SCIENCES CORP 69,430 0.0355
ARKK 28 May 2021 Buy EXAS EXACT SCIENCES CORP 103,200 0.0544
ARKK 27 May 2021 Buy EXAS EXACT SCIENCES CORP 15,315 0.0079
ARKK 21 May 2021 Buy EXAS EXACT SCIENCES CORP 5,230 0.0027
ARKK 20 May 2021 Buy EXAS EXACT SCIENCES CORP 125,929 0.0656
ARKG 14 May 2021 Buy EXAS EXACT SCIENCES CORP 18,300 0.0229
ARKG 13 May 2021 Buy EXAS EXACT SCIENCES CORP 184,139 0.2243
ARKK 12 May 2021 Buy EXAS EXACT SCIENCES CORP 322,080 0.1578
ARKG 5 May 2021 Buy EXAS EXACT SCIENCES CORP 110,016 0.1429
ARKK 4 May 2021 Sell EXAS EXACT SCIENCES CORP 187,662 0.1012
ARKK 19 Apr 2021 Buy EXAS EXACT SCIENCES CORP 27,329 0.0146
ARKK 16 Apr 2021 Buy EXAS EXACT SCIENCES CORP 49,345 0.0254
ARKK 15 Apr 2021 Buy EXAS EXACT SCIENCES CORP 28,354 0.0145
ARKK 14 Apr 2021 Buy EXAS EXACT SCIENCES CORP 136,900 0.0716
ARKK 13 Apr 2021 Buy EXAS EXACT SCIENCES CORP 240,055 0.1221
ARKK 12 Apr 2021 Buy EXAS EXACT SCIENCES CORP 33,361 0.0173
ARKK 3 Mar 2021 Buy EXAS EXACT SCIENCES CORP 62,847 0.0362
ARKK 2 Mar 2021 Buy EXAS EXACT SCIENCES CORP 191,434 0.1081
ARKK 1 Mar 2021 Buy EXAS EXACT SCIENCES CORP 7,441 0.0041
ARKK 26 Feb 2021 Buy EXAS EXACT SCIENCES CORP 81,936 0.0456
ARKK 25 Feb 2021 Buy EXAS EXACT SCIENCES CORP 25,439 0.0140
ARKG 22 Feb 2021 Buy EXAS EXACT SCIENCES CORP 194,339 0.2318
ARKG 19 Feb 2021 Buy EXAS EXACT SCIENCES CORP 100,830 0.1200
ARKK 18 Feb 2021 Buy EXAS EXACT SCIENCES CORP 75,282 0.0383
ARKG 17 Feb 2021 Buy EXAS EXACT SCIENCES CORP 250,505 0.2875
ARKK 17 Feb 2021 Buy EXAS EXACT SCIENCES CORP 401,153 0.2065
ARKG 26 Jan 2021 Buy EXAS EXACT SCIENCES CORP 44,160 0.0606
ARKG 25 Jan 2021 Buy EXAS EXACT SCIENCES CORP 191,184 0.2555
ARKG 22 Jan 2021 Buy EXAS EXACT SCIENCES CORP 70,593 0.0921
ARKG 19 Jan 2021 Buy EXAS EXACT SCIENCES CORP 107,956 0.1500
ARKG 15 Jan 2021 Buy EXAS EXACT SCIENCES CORP 73,913 0.1047
ARKK 8 Jan 2021 Buy EXAS EXACT SCIENCES CORP 102,878 0.0653
ARKK 7 Jan 2021 Buy EXAS EXACT SCIENCES CORP 104,824 0.0680
ARKG 22 Dec 2020 Buy EXAS EXACT SCIENCES CORP 65,076 0.1291
ARKG 21 Dec 2020 Buy EXAS EXACT SCIENCES CORP 1,194 0.0024
ARKG 17 Dec 2020 Buy EXAS EXACT SCIENCES CORP 28,099 0.0605
ARKK 7 Dec 2020 Buy EXAS EXACT SCIENCES CORP 211,357 0.1958
ARKK 4 Dec 2020 Buy EXAS EXACT SCIENCES CORP 75,800 0.0718
ARKK 3 Dec 2020 Buy EXAS EXACT SCIENCES CORP 126,364 0.1185
ARKK 2 Dec 2020 Buy EXAS EXACT SCIENCES CORP 82,813 0.0780
ARKG 1 Dec 2020 Buy EXAS EXACT SCIENCES CORP 75,145 0.2246
ARKG 30 Nov 2020 Buy EXAS EXACT SCIENCES CORP 9,028 0.0270
ARKG 20 Nov 2020 Buy EXAS EXACT SCIENCES CORP 77,727 0.2500
ARKK 20 Nov 2020 Buy EXAS EXACT SCIENCES CORP 91,102 0.0900
ARKK 19 Nov 2020 Buy EXAS EXACT SCIENCES CORP 159,410 0.1551
ARKG 4 Nov 2020 Buy EXAS EXACT SCIENCES CORP 48,048 0.2002
ARKK 4 Nov 2020 Buy EXAS EXACT SCIENCES CORP 55,030 0.0670
ARKK 3 Nov 2020 Buy EXAS EXACT SCIENCES CORP 109,556 0.1361
ARKG 2 Nov 2020 Buy EXAS EXACT SCIENCES CORP 46,563 0.2028
ARKK 2 Nov 2020 Buy EXAS EXACT SCIENCES CORP 211,989 0.2664
ARKG 30 Oct 2020 Buy EXAS EXACT SCIENCES CORP 44,230 0.1921
ARKK 30 Oct 2020 Buy EXAS EXACT SCIENCES CORP 153,747 0.1945
ARKG 29 Oct 2020 Buy EXAS EXACT SCIENCES CORP 16,378 0.0678
ARKK 28 Oct 2020 Buy EXAS EXACT SCIENCES CORP 311,418 0.4025
ARKG 27 Oct 2020 Buy EXAS EXACT SCIENCES CORP 77,929 0.3183
ARKK 27 Oct 2020 Buy EXAS EXACT SCIENCES CORP 510,999 0.6193
ARKG 28 Sep 2020 Sell EXAS EXACT SCIENCES CORP 10,000 0.0447
ARKG 24 Sep 2020 Sell EXAS EXACT SCIENCES CORP 100,735 0.4504
ARKG 17 Sep 2020 Buy EXAS EXACT SCIENCES CORP 92,037 0.3169
ARKG 16 Sep 2020 Buy EXAS EXACT SCIENCES CORP 264,702 0.9392
ARKG 14 Sep 2020 Buy EXAS EXACT SCIENCES CORP 122,419 0.4644
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.